JP2023055884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023055884A5 JP2023055884A5 JP2023015050A JP2023015050A JP2023055884A5 JP 2023055884 A5 JP2023055884 A5 JP 2023055884A5 JP 2023015050 A JP2023015050 A JP 2023015050A JP 2023015050 A JP2023015050 A JP 2023015050A JP 2023055884 A5 JP2023055884 A5 JP 2023055884A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- exogenous gene
- engineered
- endogenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/076798 WO2018073391A1 (en) | 2016-10-19 | 2017-10-19 | Targeted gene insertion for improved immune cells therapy |
| EPPCT/EP2017/076798 | 2017-10-19 | ||
| EP2018053343 | 2018-02-09 | ||
| EPPCT/EP2018/053343 | 2018-02-09 | ||
| PCT/EP2018/055957 WO2019076486A1 (en) | 2017-10-19 | 2018-03-09 | TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY |
| JP2020521596A JP7621795B2 (ja) | 2017-10-19 | 2018-03-09 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521596A Division JP7621795B2 (ja) | 2017-10-19 | 2018-03-09 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023055884A JP2023055884A (ja) | 2023-04-18 |
| JP2023055884A5 true JP2023055884A5 (enExample) | 2023-10-05 |
Family
ID=66173541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521596A Active JP7621795B2 (ja) | 2017-10-19 | 2018-03-09 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
| JP2023015050A Pending JP2023055884A (ja) | 2017-10-19 | 2023-02-03 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521596A Active JP7621795B2 (ja) | 2017-10-19 | 2018-03-09 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12209125B2 (enExample) |
| EP (2) | EP3684919A1 (enExample) |
| JP (2) | JP7621795B2 (enExample) |
| KR (2) | KR20200075851A (enExample) |
| CN (1) | CN111511903B (enExample) |
| AU (2) | AU2018353112B2 (enExample) |
| CA (1) | CA3084476A1 (enExample) |
| IL (1) | IL273828B2 (enExample) |
| MX (1) | MX2020004444A (enExample) |
| WO (2) | WO2019076486A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11767512B2 (en) * | 2017-04-13 | 2023-09-26 | Cellectis | Sequence specific reagents targeting CCR5 in primary hematopoietic cells |
| WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
| CN111511903B (zh) | 2017-10-19 | 2024-10-11 | 塞勒克提斯公司 | 用于改善的免疫细胞疗法的nk抑制剂基因的靶向基因整合 |
| US20200054675A1 (en) | 2018-06-01 | 2020-02-20 | Washington University | Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy |
| US12378572B2 (en) | 2018-09-07 | 2025-08-05 | Crispr Therapeutics Ag | Universal donor cells |
| WO2020084034A1 (en) | 2018-10-26 | 2020-04-30 | F. Hoffmann-La Roche Ag | Multispecific antibody screening method using recombinase mediated cassette exchange |
| CN110055224B (zh) * | 2019-04-03 | 2023-06-30 | 深圳市体内生物医药科技有限公司 | 一种基因修饰的免疫细胞及其制备方法和应用 |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| AU2020265749A1 (en) * | 2019-05-01 | 2022-01-06 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods |
| BR112021026382A2 (pt) * | 2019-06-27 | 2022-02-08 | Crispr Therapeutics Ag | Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer |
| BR112021026416A8 (pt) * | 2019-06-28 | 2022-06-28 | Cafa Therapeutics Ltd | Célula resistente à rejeição imune a transplante, e, métodos para impedir ou regular rejeição imune a transplante e para impedir ou regular o ataque de célula nk em células exógenas |
| US11118196B2 (en) | 2019-09-05 | 2021-09-14 | Crispr Therapeutics Ag | Universal donor cells |
| KR20220058579A (ko) | 2019-09-05 | 2022-05-09 | 크리스퍼 테라퓨틱스 아게 | 보편적 공여자 세포 |
| WO2021055915A1 (en) * | 2019-09-20 | 2021-03-25 | The University Of North Carolina At Chapel Hill | Modified t cells and methods of preparing the same |
| US20230076768A1 (en) | 2020-01-14 | 2023-03-09 | Synthekine, Inc. | IL2 Orthologs and Methods of Use |
| KR20230024967A (ko) * | 2020-06-11 | 2023-02-21 | 노파르티스 아게 | Zbtb32 억제제 및 이의 용도 |
| WO2021263075A1 (en) * | 2020-06-26 | 2021-12-30 | St. Jude Children's Research Hospital, Inc. | Methods of generating an activation inducible expression system in immune cells |
| EP3943097A1 (en) * | 2020-07-24 | 2022-01-26 | AB2 Bio SA | Car-t cell therapy |
| WO2022020860A2 (en) * | 2020-07-24 | 2022-01-27 | Board Of Regents, The University Of Texas System | Engineered t cells and tumor-infiltrating lymphocytes to increase tumor killing |
| US20230416786A1 (en) | 2020-11-30 | 2023-12-28 | Cellectis Sa | Use of aminoquinoline compounds for higher gene integration |
| WO2022143783A1 (en) * | 2020-12-29 | 2022-07-07 | Edigene Therapeutics (Beijing) Inc. | Methods of identifying t-cell modulating genes |
| WO2022144856A1 (en) | 2020-12-31 | 2022-07-07 | Crispr Therapeutics Ag | Universal donor cells |
| AU2022267804A1 (en) * | 2021-04-30 | 2023-12-14 | Cellectis S.A. | New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy |
| MX2023015153A (es) * | 2021-07-01 | 2024-04-16 | Ningbo T Maximum Biopharmaceuticals Co Ltd | Polipéptido de unión a antígeno que se dirige a b7h3 y aplicación del mismo. |
| EP4386010A4 (en) * | 2021-08-12 | 2025-02-26 | Cure Genetics Co., Ltd. | MODIFIED CELL AND MANUFACTURING METHOD AND USE THEREOF |
| US20250249100A1 (en) * | 2022-04-25 | 2025-08-07 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for preventing t cell exhaustion |
| CN115820697B (zh) * | 2022-09-23 | 2024-07-30 | 中国海洋大学 | 一种免疫细胞及其制备方法和应用 |
| EP4698670A1 (en) * | 2023-04-20 | 2026-02-25 | Peter MacCallum Cancer Institute | Compositions and methods for immunotherapy - ii |
| WO2024258835A1 (en) * | 2023-06-16 | 2024-12-19 | The Trustees Of Columbia University In The City Of New York | Removal of endogenous tcr chains for enhanced tcr-based immunotherapies |
| TW202509218A (zh) * | 2023-07-12 | 2025-03-01 | 亨利傑克森軍方醫學基金會 | 用於抑制自然殺手細胞之組合物及方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| AU6704794A (en) | 1993-04-13 | 1994-11-08 | Sloan-Kettering Institute For Cancer Research | Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| WO1997033988A1 (en) | 1996-03-12 | 1997-09-18 | Sloan-Kettering Institute For Cancer Research | Double mutants of dihydrofolate reductase and methods of using same |
| EP1147209A2 (en) | 1999-02-03 | 2001-10-24 | The Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| AU4328801A (en) | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
| WO2004067753A2 (en) | 2003-01-28 | 2004-08-12 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
| EP1620537B1 (en) | 2003-03-14 | 2012-10-24 | Cellectis SA | Large volume ex vivo electroporation method |
| EP3456826B1 (en) | 2009-12-10 | 2023-06-28 | Regents of the University of Minnesota | Tal effector-mediated dna modification |
| WO2012098238A1 (en) * | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
| DK2699593T4 (da) * | 2011-04-20 | 2021-02-08 | Univ Washington Through Its Center For Commercialization | Beta-2 mikroglobulin-deficiente celler |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| WO2013188873A1 (en) * | 2012-06-15 | 2013-12-19 | Gencia Corporation | Compositions and methods for enhancing immune responses |
| AU2013329186B2 (en) * | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US9890393B2 (en) * | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
| WO2015136001A1 (en) * | 2014-03-11 | 2015-09-17 | Cellectis | Method for generating t-cells compatible for allogenic transplantation |
| MX2017004603A (es) * | 2014-10-07 | 2017-06-30 | Cellectis | Metodo para modular actividad de celulas inmunes inducidas por car. |
| KR20170137079A (ko) * | 2015-03-11 | 2017-12-12 | 셀렉티스 | 그것들의 지속을 증가시키기 위한 동종이계 t 세포의 조작 및/또는 환자들 내로 이식 방법들 |
| KR20240132525A (ko) * | 2015-04-06 | 2024-09-03 | 리제너론 파아마슈티컬스, 인크. | 비인간 동물에서의 인간화 t 세포 매개 면역반응 |
| CN107921148A (zh) * | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
| IL295616A (en) * | 2015-07-31 | 2022-10-01 | Us Health | Adapted cells and treatment methods |
| WO2017049266A2 (en) * | 2015-09-18 | 2017-03-23 | The Regents Of The University Of California | Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof |
| AU2016349504B2 (en) * | 2015-11-04 | 2023-02-09 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| EP3384294B1 (en) | 2015-12-04 | 2021-10-13 | Juno Therapeutics, Inc. | Methods and compositions related to toxicity associated with cell therapy |
| AU2017207936A1 (en) * | 2016-01-15 | 2018-07-26 | Etubics Corporation | Methods and compositions for T-cell immunotherapy |
| KR20190049887A (ko) * | 2016-09-29 | 2019-05-09 | 난트케이웨스트, 인크. | 감소된 면역원성을 갖는 hla 클래스 i-결핍 nk-92 세포 |
| CN106636090B (zh) * | 2016-10-11 | 2019-08-09 | 上海优卡迪生物医药科技有限公司 | 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用 |
| CN108148863B (zh) * | 2016-12-05 | 2019-12-17 | 上海优卡迪生物医药科技有限公司 | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 |
| CN111511903B (zh) | 2017-10-19 | 2024-10-11 | 塞勒克提斯公司 | 用于改善的免疫细胞疗法的nk抑制剂基因的靶向基因整合 |
-
2018
- 2018-03-09 CN CN201880082153.1A patent/CN111511903B/zh active Active
- 2018-03-09 CA CA3084476A patent/CA3084476A1/en active Pending
- 2018-03-09 JP JP2020521596A patent/JP7621795B2/ja active Active
- 2018-03-09 KR KR1020207014099A patent/KR20200075851A/ko not_active Ceased
- 2018-03-09 WO PCT/EP2018/055957 patent/WO2019076486A1/en not_active Ceased
- 2018-03-09 KR KR1020247043433A patent/KR20250007705A/ko active Pending
- 2018-03-09 EP EP18719441.0A patent/EP3684919A1/en active Pending
- 2018-03-09 AU AU2018353112A patent/AU2018353112B2/en active Active
- 2018-03-09 US US16/755,082 patent/US12209125B2/en active Active
- 2018-03-09 IL IL273828A patent/IL273828B2/en unknown
- 2018-03-09 MX MX2020004444A patent/MX2020004444A/es unknown
- 2018-04-16 WO PCT/EP2018/059692 patent/WO2019076489A1/en not_active Ceased
- 2018-04-16 EP EP18722412.6A patent/EP3673049A1/en active Pending
- 2018-04-16 AU AU2018351689A patent/AU2018351689B2/en active Active
- 2018-04-16 US US16/755,093 patent/US12221478B2/en active Active
-
2023
- 2023-02-03 JP JP2023015050A patent/JP2023055884A/ja active Pending